Teriflunomide reduces MS relapse rate vs. placebo

sanofi-aventis Group (Euronext:SAN; NYSE:SNY) reported additional data from the Phase III TEMSO trial of teriflunomide to treat relapsing multiple sclerosis (MS). Once-daily 7 and 14 mg oral doses of the dihydroorotate dehydrogenase (DHODH) inhibitor significantly reduced annualized relapse rate from baseline to two years by 31.2% and 31.5%, respectively, vs. placebo. The low- and high-doses of teriflunomide led to annualized relapse rates of 0.37 and 0.36 vs. 0.54 for placebo (p=0.0002 and p=0.0005, respectively). The double-blind, international trial enrolled 1,088 patients. Data were presented at the European Committee for Treatment and Research in Multiple Sclerosis meeting in Gothenburg.

The pharma reported in August that teriflunomide met the primary endpoint of significantly reducing annualized relapse rate from baseline to two years vs. placebo. ...